XERS Q1 2025 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$960M

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$60M+47.9% YoY

Gross Profit

$51M85.5% margin

Operating Income

-$3M-5.1% margin

Net Income

-$9M-15.3% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$315M

Total Liabilities

$351M

Stockholders' Equity

-$35M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$60M	$41M	+47.9%
Gross Profit	$51M	$35M	+48.2%
Operating Income	-$3M	-$14M	+78.3%
Net Income	-$9M	-$19M	+51.4%

Revenue Segments

Product

$58M83%

Keveyis

$11M17%